The standard practice of a 6-8 cycle chemotherapy induction followed by maintenance wasn't a deliberate trial design. It evolved organically from patient intolerance to cumulative toxicities like neuropathy, a limitation newer, less toxic drugs like TDXD don't necessarily share.

In advanced gastroesophageal cancer, a common clinical practice for patients achieving a complete response on immunotherapy is to stop treatment after two years. For those with residual disease confirmed by biopsy, clinicians advocate for extending therapy beyond this point, contingent on payer approval.

A patient's reminder that even clinically-graded "mild" side effects like grade 2 diarrhea can be debilitating highlights a disconnect between clinical assessment and patient experience. This underscores the need for oncologists to consider the real-world impact of toxicities, like the ability to leave the house, when choosing a treatment regimen.

For patients over 75 with metastatic gastric cancer, a common practice is to reduce the oxaliplatin dose from 85 to 65 mg/m² and universally omit the 5-FU bolus from the FOLFOX regimen. This pragmatic approach aims to maintain efficacy while minimizing toxicity in a more vulnerable population.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

As a practical standard of care for elderly patients, one clinician universally avoids the 5-FU bolus in metastatic settings and reduces the oxaliplatin dose in the FOLFOX regimen from 85 mg/m² to 65 mg/m² for most patients over age 75. This adjustment balances efficacy with improved tolerability in a more vulnerable population.

With colorectal cancer rates rising in young adults, the long-term toxicity of oxaliplatin-induced peripheral neuropathy is a graver concern. A 30-year-old patient could face debilitating side effects for 40-50 years, fundamentally altering the risk-benefit calculation for adjuvant therapy.

Despite a study showing a minor hazard ratio benefit for a FLOT-like regimen over FOLFOX in the metastatic setting, experts advise against it. The significant increase in toxicity outweighs the small efficacy advantage, especially in symptomatic metastatic patients who are often nutritionally deficient and less able to tolerate aggressive chemotherapy.

As survival times for metastatic gastric cancer patients extend, managing long-term toxicity is paramount. Clinicians typically administer only 6-8 cycles of oxaliplatin to prevent severe, cumulative peripheral neuropathy, allowing for longer, better-tolerated maintenance therapy with biologics.